Nurix Therapeutics has been granted a patent for compounds that degrade BTK through a ubiquitin proteolytic pathway. The invention includes pharmaceutical compositions and treatment methods for various diseases. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nurix Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of January 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11866442B2) discloses a compound of Formula (A) and its pharmaceutically acceptable salts, with various specific configurations outlined in the claims. The compound is designed to target and degrade Bruton's tyrosine kinase, offering potential therapeutic applications in treating diseases or disorders mediated by this enzyme. The patent also covers a method of treating conditions such as cancer, hematological cancers like leukemia, autoimmune diseases, and a wide range of specific autoimmune conditions. Additionally, the patent includes the formulation of pharmaceutical compositions containing the compound along with suitable carriers, vehicles, or adjuvants for effective delivery.

The patent claims detail the structural variations and substitutions within the compound of Formula (A) and its pharmaceutically acceptable salts, emphasizing the specificity required for targeting Bruton's tyrosine kinase. The method outlined in the patent for treating diseases mediated by this kinase, particularly cancer and autoimmune disorders, showcases the potential therapeutic benefits of the compound. The extensive list of autoimmune diseases mentioned in the claims highlights the broad spectrum of conditions that could potentially benefit from the compound's mechanism of action. Overall, the patent provides a comprehensive framework for the development and application of the disclosed compound in the field of pharmaceuticals, particularly in addressing diseases associated with Bruton's tyrosine kinase.

To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies